Literature DB >> 10796801

Lisuride for levodopa-induced complications in Parkinson's disease.

C E Clarke1, J M Speller.   

Abstract

OBJECTIVES: To compare the efficacy and safety of adjuvant lisuride therapy versus placebo in patients with Parkinson's disease, already established on levodopa and suffering from motor complications. SEARCH STRATEGY: Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Cambridge Laboratories and Roche Products Limited. SELECTION CRITERIA: Randomised controlled trials of lisuride versus placebo in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy. DATA COLLECTION AND ANALYSIS: Data was to be abstracted independently by each author and differences settled by discussion. MAIN
RESULTS: No randomised controlled trials comparing lisuride with placebo in advanced Parkinson's disease with motor complications were found. REVIEWER'S
CONCLUSIONS: Well designed randomised controlled trials demonstrating efficacy and safety are required before the use of lisuride in later Parkinson's disease can be supported.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796801      PMCID: PMC7025784          DOI: 10.1002/14651858.CD001515

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  6 in total

1.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

Authors:  G Block; C Liss; S Reines; J Irr; D Nibbelink
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

2.  Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease.

Authors:  G Stern; A Lees
Journal:  Adv Neurol       Date:  1987

3.  Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.

Authors:  U K Rinne
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

4.  When should levodopa be started?

Authors:  N Quinn; P Critchley; D Parkes; C D Marsden
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

5.  Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.

Authors: 
Journal:  BMJ       Date:  1993-08-21

6.  Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy.

Authors:  A H Rajput; W Stern; W H Laverty
Journal:  Neurology       Date:  1984-08       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.